Open Journal of Nephrology

Volume 2, Issue 4 (December 2012)

ISSN Print: 2164-2842   ISSN Online: 2164-2869

Google-based Impact Factor: 0.44  Citations  

Pharmacological Adjuvants to Limit Erythropoietin Stimulating Agents Exposure

HTML  Download Download as PDF (Size: 262KB)  PP. 86-96  
DOI: 10.4236/ojneph.2012.24015    5,850 Downloads   8,605 Views  Citations


Anemia in chronic kidney disease (CKD) is common, causing morbidity and mortality, and is primarily due to reduced erythropoietin (EPO) release and, to a lesser degree, shortened red cell survival. Erythropoietin Stimulating Agents like epoetin Alfa and darbepoetin alpha are used commonly to treat this form of anemia. Recent evidence suggests increased morbidity and mortality associated with higher hemoglobin in the setting of these agents use. Whether these complications are due to higher dose of erythropoietin or its resistance (i.e. inflammation), or achieving a higher hemoglobin remains unclear. Tightening restrictions on these agents has led to increase interest in the use of non-ESA adjuvants to improve erythropoiesis. This review will highlight the most promising of these agents.

Share and Cite:

I. Masood and G. Teehan, "Pharmacological Adjuvants to Limit Erythropoietin Stimulating Agents Exposure," Open Journal of Nephrology, Vol. 2 No. 4, 2012, pp. 86-96. doi: 10.4236/ojneph.2012.24015.

Copyright © 2021 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.